Explainer: Can J&J finally move past talc litigation?

• The settlement is voluntary and does not bind unwilling participants or future claimants, unlike J&J's two previous bankruptcy attempts that were both thrown out of court
• Claims will be paid in full in less than two years under the new deal, compared to 25 years under the rejected bankruptcy settlement
• J&J remains exposed to future litigation from people who may develop ovarian cancer later, as the disease can have a latency period of decades between exposure and detection

Summary

Johnson & Johnson has announced a settlement worth at least $5.5 billion to resolve tens of thousands of lawsuits alleging its talc-based baby powder caused ovarian cancer. The litigation has plagued the healthcare giant for over a decade, resulting in billions in verdicts, settlements, and legal costs, though J&J maintains its products are safe based on decades of scientific testing.

Key Settlement Terms:

• The deal requires acceptance from plaintiffs representing 95% of approximately 76,000 ovarian cancer claims
• Approval could occur within months, according to supporting plaintiffs' lawyers
• Claims will be paid in full within two years, significantly faster than previous proposals

Previous Failed Attempts:

J&J twice attempted to resolve the litigation through bankruptcy by creating subsidiaries, transferring talc liabilities, and filing for bankruptcy protection. Both attempts were rejected by courts, with critics arguing that a financially healthy company shouldn't exploit bankruptcy protections designed for distressed businesses.

What's Different:

Unlike previous bankruptcy proposals, this settlement is voluntary and doesn't bind unwilling participants or future claimants. However, this leaves J&J exposed to potential litigation from individuals who develop ovarian cancer years later, given the disease's decades-long latency period.

Market Implications:

Leading plaintiffs' law firms have expressed confidence the deal will succeed, particularly following a recent court ruling that restricted plaintiffs' ability to prove their cases and tightened standards for scientific evidence admissibility. Some firms are still reviewing the proposal before recommending it to clients.

The settlement represents J&J's most viable path yet to resolving this long-standing legal challenge, though complete closure remains uncertain due to future claim exposure.